Amarin AMRN
Amarin FY 2023: revenue $306.9M, down 17%; diluted EPS −$0.15
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-022636
- Document
- 10-K
- Exhibit 10.43
- Material contract
Key figures from this report
These are the numbers Amarin reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$306.9M−17% from $369.2M in FY 202210-K income statement, on EDGAR
- Net income−$59.1MAgainst −$105.8M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$0.15Against −$0.26 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$199.3M−8% from $217.7M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$6.9MAgainst −$180.1M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
- Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
- Usana Health Sciences USNA public float $328M, Jun 27, 2025
- Emergent BioSolutions EBS public float $343M, Jun 30, 2025
- Altimmune ALT public float $327M, Jun 30, 2025
